Pandemic prevention

#Infectious diseases #Pandemic prevention #University of Texas

Research collaboration to ‘strengthen pandemic preparedness’ 

Life science company ProImmune has announced a collaboration with The University of Texas Medical Branch (UTMB) to partner on research into infectious diseases.  The collaboration will combine ProImmune’s Ankyron target binding reagent technology with expertise at the Galveston National Laboratory (GNL), part of UTMB, in the immunopathology of emerging viruses.   Under the… Read More

#News

Illustration of a virus
#Biomedical Advanced Research and Development Authority (BARDA) #Evotec #Monoclonal antibodies #Pandemic prevention

Just – Evotec Biologics enters $10m agreement with BARDA

Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimisation for a monoclonal antibody cocktail.  The therapy will target filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).  The multi-year… Read More

#Business & Investment #News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step forward in global… Read More

#Business & Investment #News

Bubonic plague bacteria
#Bacteria #Clinical trial #Pandemic #Pandemic prevention

First clinical evidence for bubonic plague treatment

Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.  The IMASOY trial provides the first robust evidence of the efficacy and safety of two common treatment regimens. … Read More

#News

Monkeypox virus
#CEPI #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Immune marker playbooks support vaccine development

CEPI and PATH are joining forces to create playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.  Supported by $8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights… Read More

#News

#Adaptvac #CEPI #Disease X #Ebola virus #Immunology / Virology & Vaccines #Pandemic prevention

All-in-one vaccine development backed by $12.4m funding

Scientists at Denmark’s Adaptvac will lead the development of a new vaccine that could provide all-in-one protection against multiple deadly viruses, including Ebolavirus Zaire, Sudan Ebolavirus and Marburg.  Backed by $12.4 million of funding from CEPI and the European Union’s Horizon Europe programme, a global consortium led… Read More

#Editor's Choice #News

#Antibodies #Monoclonal antibodies #Pandemic prevention #Pandemic response

Polyclonal and recombinant antibody development

Joerg Schuettrumpf, Chief Scientific Innovation Officer at Grifols, discusses advancements in antibody therapies, focusing on IgA, IgM, and recombinant polyclonal technologies to enhance treatment efficacy, scalability, and preparedness for global health challenges. IgA and IgM therapies The therapeutic antibody field is progressing rapidly, says Schuettrumpf, with key advances in broad-spectrum… Read More

#Exclusive Content

#Immunology / Virology & Vaccines #Infectious diseases #Pandemic prevention #Pandemic response

Preparing for the next infectious disease pandemic

Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development. Introduction Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant… Read More

#Exclusive Content

#Coronavirus #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Pandemic prevention #University of Cambridge

‘Proactive’ vaccine protects against unknown future coronaviruses

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. This approach to vaccine development is called ‘proactive vaccinology’, where scientists build a vaccine before… Read More

#Editor's Choice #News

Vaccine discovery
#Covid-19 #Immunity #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Accelerating recombinant protein vaccine discovery

Listen to this article on the DDW Podcast: Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason), Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. Technologies that hasten the pathway from vaccine discovery to… Read More

#Exclusive Content

Patient receiving vaccine
#CEPI #Immunology / Virology & Vaccines #Nipah Virus #Pandemic prevention #University of Oxford

In-human trial begins for first potential Nipah virus vaccine

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Nipah virus is mostly found in South-East Asia that can be fatal in up to 75% of cases. Despite the first outbreaks occurring 25 years ago in… Read More

#News

Doctor prepares vaccine
#Funding #Immunology #Immunology / Virology & Vaccines #Pandemic prevention #University of Oxford

University of Oxford receives £7.8 million to fight pandemic threats

The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential. The awards will fund research into… Read More

#News

Antibodies attack Covid-19
#Covid-19 #Harvard Medical School #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #University of Oxford

AI tool predicts new viral variants and could improve vaccines

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new… Read More

#News #Trending News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

Chickens
#Genetics / genomics #Immunology / Virology & Vaccines #Influenza #Pandemic prevention

Human gene that defends against avian flu discovered

New research has found a key human gene responsible for blocking most avian flu viruses from spilling over into people. The international study into the pandemic potential of avian flu, which is led by scientists at the MRC-University of Glasgow Centre for Virus Research (CVR), identified… Read More

#Editor's Choice #News

Vaccine production
#Emory University #Immunology / Virology & Vaccines #Pandemic prevention #Partnership #University of Queensland

Brisbane-Atlanta partnership focuses on pandemic response

The University of Queensland (UQ), Australia, and Emory University in Atlanta, US, have committed to scaling up their collaboration to focus on pandemic preparedness and regional disease prevention. UQ Vice-Chancellor Professor Deborah Terry said the Brisbane-Atlanta partnership will bring together world-class researchers to accelerate the development… Read More

#News